Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Immutep(LAG-3 specialist), belangrijke speler in een nieuw checkpoint voor blockbuster drugs

250 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 13 »» | Laatste | Omlaag ↓
  1. forum rang 4 Dag Trader 22 juni 2021 10:31
    weet niet of ik het kan vergelijken, maar in Nov.2020 lijkt er alleen op de dag van het PB een reactie te zijn geweest.
    op de dagen van settlement en issue geen grote uitslagen. Stelt mij wel gerust.

    PB op 19 nov.2020
    Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

    Timetable
    Settlement of the Placement is expected to occur on Tuesday, 24 November 2020 with the issue of New Shares expected to occur on Wednesday, 25 November 2020.

    vrijdag 16 nov. 2020 close 2,02
    maandag 19 nov. 2020 close 1,90
    22 nov. 1,90
    23 nov. 1,89
    24 nov. 1,91
    25 nov. 1,87
    27 nov. 1,90
    30 nov. 1,97
    07 dec. 2,09
    10 dec. 5,69
    24 dec. 2,94
  2. forum rang 4 Maisha marefu 22 juni 2021 13:01
    Mooi speurwerk Dag Trader!

    Denk niet dat de koers grote sprongen gaat maken als de aangekondigde aandelen in omloop komen. Naar mijn mening al verwerkt in de koers.

    Ik verwacht tegen het einde van het jaar een hele mooie stijging van het aandeel. Uiteraard heb ik geen glazen bol...en kan ik ook volledig mis zijn. Maar de signalen zijn positief!
  3. forum rang 5 Goudmijn64 23 juni 2021 16:42
    het is wel even doorbijten met Immutep.

    Tijd voor wat herstel. Wat is daarvoor nodig?
    Een mooi PB, adviesverhoging of gewoon technisch herstel?

    Voorlopig is de uitgifte van de aandelen nog steeds niet volledig verwerkt in de markt/koers.

    Of straks een ommekeer? de avond is nog jong.
  4. evenaar 2 juli 2021 13:11
    Dit is het transcript van medscape.

    Hello. I'm Dr Jeffrey Weber. I'm a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone Health in New York City. Today I'll be commenting on two studies on melanoma treatment presented at the oral sessions of this year's American Society of Clinical Oncology (ASCO) meeting.

    RELATIVITY-047 was a randomized study that included more than 700 patients with previously untreated melanoma. Patients were randomly assigned to receive either relatlimab (RELA), an antibody that blocks the lymphocyte activation gene 3 (LAG-3), plus nivolumab (NIVO) vs NIVO alone. The primary endpoint of this trial was investigator-called progression-free survival (PFS). The secondary endpoints were response rate and overall survival.

    This was a well-conducted, well-balanced, randomized phase 3 trial. All of the usual prognostic factors were well matched, including gender, age, performance status, serum LDH, tumor burden, and LAG-3 expression. Previous trials of second-line treatment have shown that a high LAG-3 expression in the tumor was associated with a better response. Overall, 75% of the patients in this study had LAG-3 in more than 1% of the tumor, presumably mostly on infiltrating immune cells, with 25% having LAG-3 in less than 1%, probably meaning that they were essentially LAG-3 negative.


    The median PFS in the RELA/NIVO combination arm was 10.1 months vs 4.6 months for NIVO alone, with a hazard ratio of 0.75 and a P value of .005. The 12-month PFS was 47% for the combo vs 36% for NIVO alone, clearly a winner for the combination.

    Benefit was seen in patients who were LAG-3 positive and also in those who were LAG-3 negative, which frankly is surprising. If you look at the PFS curves for LAG-3 expression greater than 1%, the median PFS for the RELA/NIVO group was 12 months vs 4.7 months for NIVO alone. For the minority of patients with a LAG-3 of less than 1%, PFS was around 4.8 months vs 2.8 months for NIVO alone — not quite as good, meaning the patients who were LAG-3 negative clearly had less impressive, less immunogenic, less inflamed tumors. LAG-3 is another checkpoint like PD-1, so that antibody will do better in the more inflamed tumors.

    The rate of grade 3/4 treatment-related, immune-related adverse events was about 18.9% for RELA/NIVO, compared with 9.7% for NIVO alone. There were three deaths in the RELA/NIVO group vs two deaths in the NIVO alone group. One death in the NIVO alone arm was related to myocarditis; three episodes of myocarditis, presumably not leading to death, occurred in the RELA/NIVO arm. The distribution of immune-related adverse events was typical, as you would expect with a slight increase in the combination arm, but again, I think quite tolerable.

    Bottom line: RELATIVITY-047 was the first phase 3 study to validate dual LAG-3 and PD-1 inhibition, and I think this was a clear winner. This provided clear evidence of greater activity in the RELA/NIVO combination than in NIVO alone.

    This presentation came right on the heels of another interesting study, presented by Rodabe Amaria, of neoadjuvant and adjuvant RELA/NIVO in patients with resectable stage III melanoma. A total of 30 patients received neoadjuvant RELA/NIVO, followed by resection, followed by adjuvant RELA/NIVO, something that has not been done before. The primary endpoints were the determination of the pathologic complete response (PCR) rate and the major pathologic response rates.

    Most of the 30 participants had an ECOG performance status of zero; the majority had stage IIIB or IIIC disease, with a sprinkling of patients with stage IIID or IV. Twenty-nine patients underwent surgery; one could not because of toxicity.

    The PCR rate was 59%, which is pretty darn impressive, with an additional 7% of patients at 90% PCR or better. A total of 66% of the patients had a major pathologic response rate. Those are impressive data. If you look at the overall radiographic response rate, it matches the PCR rate of 57%. I would agree with the investigator in that trial, however, that the radiologic response underestimates the pathologic response because the major response rate was 66%, but only 57% by radiologic assessment. Of the patients who had a major 90% or more pathologic complete response at 16 months of follow-up, no one has relapsed and the relapse rate in everyone else is a pretty healthy 60% at 16 months. Those are impressive data. In all, 26% of the patients had grade 3 immune-related adverse events in the adjuvant setting, with no significant dose-limiting toxicity in the patients who received two 4-week cycles of RELA/NIVO in the neoadjuvant setting.

    This is impressive data that sets up RELA/NIVO as a favored neoadjuvant regimen. It could replace ipilimumab/NIVO as the favored neoadjuvant immunotherapy regimen.

    This is Dr Jeffrey Weber. Please do contact me with questions or comments. Thank you for your attention.
  5. forum rang 5 Goudmijn64 6 juli 2021 08:35
    quote:

    Kijkboek schreef op 6 juli 2021 03:44:


    www.immutep.com/files/content/investo...

    Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in
    HNSCC



    Dit is een mooi bericht. Immutep is op de goede weg.
    Jammer dat de koers in Australie niet uitbundiger reageert.

    Hopelijk is de neergaande trend gebroken na een gematigde positieve dag.

    Benieuwd hoe het op de beurs in de VS zal gaan met Immutep.
  6. M c M 6 juli 2021 16:24
    quote:

    Goudmijn64 schreef op 6 juli 2021 11:05:


    Premarket gaat lekker.
    Ik ben benieuwd hoe snel we weer de 5 usd gaan aantikken.
    Dat moet lukken met dit pb.


    Bijzondere reactie in de USA... nadat ik de dag na de emissie uit paniek veel te vroeg verkocht à 4,15 ben ik weer volledig terug ingestapt op 3,85. Zal uiteraard weer veel te vroeg zijn, maar dit is toch gewoon prima en voor mij ook onverwacht nieuws!
250 Posts
Pagina: «« 1 ... 5 6 7 8 9 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 807,64 +0,27%
EUR/USD 1,1627 +0,00%
FTSE 100 7.190,30 -0,45%
Germany40^ 15.512,30 +0,26%
Gold spot 1.786,96 +0,23%
NY-Nasdaq Composite 15.215,70 +0,62%

Stijgers

RANDST...
+5,46%
BESI
+4,73%
ASMI
+3,08%
Pharming
+2,50%
TomTom
+2,47%

Dalers

Intert...
-5,15%
Arcelo...
-3,73%
OCI
-2,35%
Fugro
-2,33%
Corbion
-2,14%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links